Leerink Partnrs Has Bearish Outlook for VIRX FY2024 Earnings

Viracta Therapeutics, Inc. (NASDAQ:VIRX) – Equities researchers at Leerink Partnrs cut their FY2024 earnings estimates for Viracta Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($0.80) per share for the year, down from their previous estimate of ($0.69). The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($0.80) per share. Leerink Partnrs also issued estimates for Viracta Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.40) EPS.

Other analysts have also issued reports about the company. Royal Bank of Canada cut their price target on Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Leerink Partners lowered shares of Viracta Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $5.00 to $3.00 in a report on Friday, August 16th.

Viracta Therapeutics Price Performance

NASDAQ VIRX opened at $0.15 on Monday. Viracta Therapeutics has a twelve month low of $0.13 and a twelve month high of $1.31. The business’s fifty day moving average is $0.22 and its 200 day moving average is $0.42. The company has a market cap of $6.08 million, a price-to-earnings ratio of -0.14 and a beta of 0.72.

Institutional Investors Weigh In On Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Viracta Therapeutics, Inc. (NASDAQ:VIRX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned 1.27% of Viracta Therapeutics as of its most recent filing with the Securities and Exchange Commission. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.